Advances in dendritic cells-based for vaccine prostate cancer

许明伟,张杰

2014-01-01

Abstract:Dendritic cell(DC) is the most powerful antigen-presenting cell(APC), which can prime naive T cell and break peripheral tolerance and thus induce tumor immune responses. DC-based active immunotherapy can extend the survival time of the patients. This review decribes advances in DC-based for vaccine prostate camcer.

What problem does this paper attempt to address?

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

JIANG Tao,XU Chuang,LIU Guo-wen,LUO Sheng-jun,GAO Ying-jie,WANG Zhe

DOI: https://doi.org/10.3969/j.issn.1007-5038.2007.02.018

2007-01-01

Abstract:Dendritic cells(DC) are the most powerful professional antigen presenting cells.Lots of studies have demonstrated that the DC vaccines play an important role in antitumor immunity.With the developments of molecular biology,immunology and genetic engineering,rapid progress has been made in DC vaccines and application of DC-based immunotherapy.In this review,the DC biological property,the relationship between the development of cancer and dendritic cell,the production of dendritic cell tumor vaccines and their use in clinical trials were discussed.It may provide valuable information with respect to DC primary study and clinical trials.
Advances in Research on Dendritic Cell-based Tumor Vaccine

Hongmin LU,Linfeng LI,Jianxin GAO

DOI: https://doi.org/10.3969/j.issn.1008-7125.2016.05.001

2016-01-01

Abstract:Although tumor immunotherapy has been proposed for many years,the consensus denoting it as an essential approach for fighting against cancer is reached only in recent years. Tumor immunotherapy can be categorized as active and passive ones. In order to successfully cure cancer,safe and efficient active immunotherapy is required. Dendritic cells (DCs)are not only the bridge linking innate and adaptive immunity,but also the key determinants of the quality of adaptive immunity:immunity versus immune tolerance. Therefore,the safe and efficient DC-based tumor-specific and broad-spectral tumor vaccine has an irreplaceable important position in tumor immunotherapy. Because of the high heterogeneity of DCs, the research on DC-based tumor vaccine has encountered a bottleneck. Here,we reviewed the progress in research on DC-based tumor vaccine and related problems needed to be resolved with the incorporation of our experiences.
Research of Dendritic Cell Tumor Vaccine

WEI Jing,WANG Bao-long

DOI: https://doi.org/10.3760/cma.j.issn.1673-4394.2012.04.005

2012-01-01

Abstract:Dendritic cell which is found as the most powerful professional antigen presenting cell (APC) at present,can activate resting T cell and make it proliferate,induce the production of antigen-specific cytotoxic T lymphocytes( CTL),thus it plays an antineoplastic immune effect.In recent years,in tumor vaccine researcher,People take a variety of strategies to prepare the DC tumor vaccine which can clear tumor cells by changing the immune system to the immune status of the tumor and strengthening active immunity against tumor.This will almost no damage to normal tissues.So it would bring prospects for clinical application.Now,several DC tumor vaccines are reviewed in this paper.
Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

Chunmei Fu,Tianle Ma,Li Zhou,Qing-Sheng Mi,Aimin Jiang

DOI: https://doi.org/10.1080/08820139.2022.2109486

2022-08-11

Immunological Investigations

Abstract:As the most potent professional antigen presenting cells, dendritic cells (DCs) have the ability to activate both naive CD4 and CD8 T cells. Recognized for their exceptional ability to cross-present exogenous antigens to prime naive antigen-specific CD8 T cells, DCs play a critical role in generating CD8 T cell immunity, as well as mediating CD8 T cell tolerance to tumor antigens. Despite the ability to potentiate host CD8 T cell-mediated anti-tumor immunity, current DC-based cancer vaccines have not yet achieved the promised success clinically with the exception of FDA-approved Provenge. Interestingly, recent studies have shown that type 1 conventional DCs (cDC1s) play a critical role in cross-priming tumor-specific CD8 T cells and determining the anti-tumor efficacy of cancer immunotherapies including immune checkpoint blockade (ICB). Together with promising clinical results in neoantigen-based cancer vaccines, there is a great need for DC-based vaccines to be further developed and refined either as monotherapies or in combination with other immunotherapies. In this review, we will present a brief review of DC development and function, discuss recent progress, and provide a perspective on future directions to realize the promising potential of DC-based cancer vaccines.

immunology
Anti-tumor Immunity with Dendritic Cells ( DC) Vaccine Modified by IL-18

王峻,何炳荣,孙宏高,邵传森,沈建根

DOI: https://doi.org/10.3969/j.issn.1008-7664.2006.01.003

2006-01-01

Abstract:Objective To explore the anti-tumor effect of dendritic cells (DC) vaccine and new immunotherapy method. Methods Cytokine interleukin-18 (IL-18) an melanoma-associated antigen gp100 were transfected into bone marrow-derived DC (IL-18/gp100-DC), which were used as vaccine to induce the protective in a B16 melanoma model. And the effect of DC vaccine were detected through ELISA, RT-PCR, FACS and MLR. Results DC vaccines were successful constructed. The effect of anti-tumor immunity in IL-18/gp100-DC was significant higher than that of IL-18-DC or gp100-DC. Conclusion The effect of anati-tumor was significanly enhanced with DC vaccine co-expressing Th1 cytokine IL-18 and gp100.
Progress in Biology of Dendritic Cells——Review

YUAN Ting-Ting,LIU Yan-Rong

2010-01-01

Abstract:As the most potent antigen-presenting cells (APC),dendritic cells are important in launching both humoral and celluar immune responses against tumor. Although the high evaluation of DC in immnunotherapy for cancer by means of DC vaccines,more studies have indicated DC is a heterogeneous population and proved that DC subsets are prominent determinants for the effectiveness of immune responses. Different DC subsets display different receptors and surface molecules,and express different sets of cytokines/chemokines,which result in distinct immunological outcomes. Clinical trials with ex vivo generated DC vaccines also manifest unexpected immunological tolerance as well as allegic response. It is essential to study the biological aspects of human DC subsets,which may be a key to the generation of novel DC-based vaccines. In this article,the progress of studies on biology of dendritic cells including their origins,differentiation,function and application of DC subsets is reviewed.
Advances in dendritic cells vaccines

吕方芳,洪小南,李进

DOI: https://doi.org/10.3969/j.issn.1007-3639.2004.01.026

2004-01-01

Abstract:Dendritic cells are now given more attention th ese years in tumor immuno-therapy. In this review, we summarized the advances o f dendritic cells vaccines and their applications in malignant tumors such as me lanoma and renal carcinoma.
The role of dendritic cells in cancer immunity and therapeutic strategies

Yunze Tai,Man Chen,Fang Wang,Yu Fan,Junlong Zhang,Bei Cai,Lin Yan,Yao Luo,Yi Li

DOI: https://doi.org/10.1016/j.intimp.2024.111548

IF: 5.714

2024-01-21

International Immunopharmacology

Abstract:Dendritic cells (DCs) are asserted as the most potent antigen-presenting cells (APCs) that orchestrate both innate and adaptive immunity, being extremely effective in the induction of robust anti-cancer T cell responses. Hence, the modulation of DCs function represents an attractive target for improving cancer immunotherapy efficacy. A better understanding of the immunobiology of DCs, the interaction among DCs, immune effector cells and tumor cells in tumor microenvironment (TME) and the latest advances in biomedical engineering technology would be required for the design of optimal DC-based immunotherapy. In this review, we focus on elaborating the immunobiology of DCs in healthy and cancer environments, the recent advances in the development of enhancing endogenous DCs immunocompetence via immunomodulators as well as DC-based vaccines. The rapidly developing field of applying nanotechnology to improve DC-based immunotherapy is also highlighted.

pharmacology & pharmacy,immunology
Advance in the Research of Tumor RNA Transfected Dendritic Cells Vaccine and Its Anti-Neoplastic Application

JIN Juan,WANG Bao-long

DOI: https://doi.org/10.3760/cma.j.issn.1673-4394.2010.01.015

2010-01-01

International Journal of Immunology

Abstract:Dendritic cell (DC) is the most powerful professional antigen presenting cell ( APC) , and plays a key role in initiating immune response. DC now has already become a new carrier in cancer immuno-therapy. In recent years, it has been discovered that RNA-transfected dendritic cell vaccine has many unique characteristics, and play an important role in the treatment of tumor. Thus, more and more studies pay close attention to it. This paper reviews the reseaches on characteristics of RNA transfected DC vaccines and the effect in tumor therapy.
Dendritic Cells Based Immunotherapy

Na Shang,Matteo Figini,Junjie Shangguan,Bin Wang,Chong Sun,Liang Pan,Quanhong Ma,Zhuoli Zhang

2017-01-01

American journal of cancer research

Abstract:Dendritic cells (DCs) are the most potent antigen-presenting cells, and tumor antigen-loaded DCs (DC-vaccines) can activate tumor-specific cytotoxic T lymphocytes (CTLs) in lymphatic tissues. DC vaccination is a newly emerging and potent form of cancer immunotherapy and has clinically relevant mechanisms of action with great potential for the systemic treatment of cancers. However, clinical trials have demonstrated relatively poor therapeutic efficacy. The efficacy of DC-vaccines is strongly influenced by various techniques for the priming antigen loading onto DCs and their ability to migrate to the draining lymph nodes (LNs). Therefore, it is critical to improve DC-vaccines homing to draining LNs after administration in order to optimize DC-based therapy for individual patients. This review underlines 1) appropriate strategy to load tumor antigens onto DCs and 2) to optimize vaccine administration methods to ensure loaded DCs can migrate to LNs, in particular, Intraperitoneal (IP) injection. IP injection of DC-based vaccine may be a potential regimen for gastrointestinal tumors including hepatocellular carcinoma (HCC) and pancreatic adenocarcinoma (PDAC) since huge populations of LNs are present throughout the gastrointestinal track. Which might improve the subsequent migration to LNs.
Advances in Preparation and Clinical Application of Dendritic Cell-Based Tumor Vaccines

邹征云,刘宝瑞

DOI: https://doi.org/10.3969/j.issn.1673-5269.2004.11.032

2004-01-01

Abstract:Dendritic cell-based tumor vaccines can induce tumor models' protectitive antitumor immunity,and these inspire us.This paper reviews current advances in the preparation and the clinical application of dendritic cell-based tumor vaccines for tumor immunotherapy.
Progress of Dendritic Cell in Tumor Immunotherapy

Zhenggang Zhu

2011-01-01

Abstract:Dendritic cell is the most potent professional antigen presenting cells in human,which can induce specific cytotoxic T lymphocyte.Along with the rapid progress of the oncology,the immunology and the molecular biology,people have studied in a deepgoing way on DC cells.Many reserches have been demonstrated that DC cells play a very vital role on antitumor immune response.Tumor immunotherapy based on DC and DC bacterin have made headway in clinical application,which will open vast vistas in oncotherapy.
Current state of knowledge and challenges for harnessing the power of dendritic cells in cancer immunotherapy

Abdullah M Shbeer

DOI: https://doi.org/10.1016/j.prp.2023.155025

Abstract:DCs have great promise for cancer immunotherapy and are essential for coordinating immune responses. In the battle against cancer, using DCs' ability to stimulate the immune system and focus it on tumor cells has shown to be a viable tactic. This study offers a thorough summary of recent developments as well as potential future paths for DC-based immunotherapy against cancer. This study reviews the many methods used in DC therapy, such as vaccination and active cellular immunotherapy. The effectiveness and safety of DC-based treatments for metastatic castration-resistant prostate cancer and non-small cell lung cancer are highlighted in these investigations. The findings indicate longer survival times and superior results for particular patient groups. We are aware of the difficulties and restrictions of DC-based immunotherapy, though. These include the immunosuppressive tumor microenvironment, the intricacy of DC production, and the heterogeneity within DC populations. More study and development are needed to overcome these challenges to enhance immunological responses, optimize treatment regimens, and increase scalability.
Dendritic cell biology and its role in tumor immunotherapy

Yingying Wang,Ying Xiang,Victoria W. Xin,Xian-Wang Wang,Xiao-Chun Peng,Xiao-Qin Liu,Dong Wang,Na Li,Jun-Ting Cheng,Yan-Ning Lyv,Shu-Zhong Cui,Zhaowu Ma,Qing Zhang,Hong-Wu Xin

DOI: https://doi.org/10.1186/s13045-020-00939-6

2020-08-03

Abstract:Abstract As crucial antigen presenting cells, dendritic cells (DCs) play a vital role in tumor immunotherapy. Taking into account the many recent advances in DC biology, we discuss how DCs (1) recognize pathogenic antigens with pattern recognition receptors through specific phagocytosis and through non-specific micropinocytosis, (2) process antigens into small peptides with proper sizes and sequences, and (3) present MHC-peptides to CD4 + and CD8 + T cells to initiate immune responses against invading microbes and aberrant host cells. During anti-tumor immune responses, DC-derived exosomes were discovered to participate in antigen presentation. T cell microvillar dynamics and TCR conformational changes were demonstrated upon DC antigen presentation. Caspase-11-driven hyperactive DCs were recently reported to convert effectors into memory T cells. DCs were also reported to crosstalk with NK cells. Additionally, DCs are the most important sentinel cells for immune surveillance in the tumor microenvironment. Alongside DC biology, we review the latest developments for DC-based tumor immunotherapy in preclinical studies and clinical trials. Personalized DC vaccine-induced T cell immunity, which targets tumor-specific antigens, has been demonstrated to be a promising form of tumor immunotherapy in patients with melanoma. Importantly, allogeneic-IgG-loaded and HLA-restricted neoantigen DC vaccines were discovered to have robust anti-tumor effects in mice. Our comprehensive review of DC biology and its role in tumor immunotherapy aids in the understanding of DCs as the mentors of T cells and as novel tumor immunotherapy cells with immense potential.

oncology,hematology
Research progress of dendritic cell and dendritic cell function and vaccine

HE Zhi-feng,WANG Zhi-yong,HU Qin-gang

2010-01-01

Abstract:Dendritic cell(DC) play a key role in systemic immune response against tumor for their ability to initiate primary immune response. The infiltration of DC with different phenotype in head and neck squamous cell carcinoma(HNSCC) patients correlates to tumor prognosis closely. This review will discuss the correlation of tumor prognosis with different subtypes of DC and their infiltration in tumor tissue. Followed by the decreased amount,abnormal maturity and dysfunction of DC in HNSCC patients,including DC in tumor tissue,lymph node and peripheral blood. And then discuss reasons for DC dysfunction and the present research on dendritic cell vaccine.
Development of Dendritic Cell Based for Tumor Gene Immunotherapy

LUO Peng,WANG Bao-Long

DOI: https://doi.org/10.3760/cma.j.issn.1673-4394.2013.02.003

2013-01-01

International Journal of Immunology

Abstract:Dendritic cells (DC) are the most potent antigen presenting cells (APC) with unique ability to directly activate naive CD4 + and CD8 + T cells.As a bridge,DCs link innate immunity with adaptive immunity.Therefore,DCs have become an attractive target for therapeutic manipulation of the immune system.In recent years,the appearance of gene modified DCs vaccines,which improve the efforts of antitumor therapy.This review will simply discuss the efforts of antitumor immune responses of the basis of gene-modified DCs vaccines.
Dendritic cells-based tumor vaccines：advances in research and practice

Yuan Yuan,Chuan Su,Yongqian Shu

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2014.17.024

2014-01-01

Abstract:Cancer is one of the top killers which threatens global people's health. Although current treatments such as surgery, radiotherapy and chemotherapy have been improved, prognosis remains unsatisfactory. Developing new therapeutic strategy is still an urgent demand. Dendritic cell vaccines based immunotherapy activated immune cells can specifically kill tumor cells by recognition of tumor-associated antigens without injuring normal cells. It has become a highlight for tumor therapy.
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations

Kyu-Won Lee,Judy Wai Ping Yam,Xiaowen Mao

DOI: https://doi.org/10.3390/cells12172147

IF: 6

2023-08-26

Cells

Abstract:In the emerging era of cancer immunotherapy, immune checkpoint blockades (ICBs) and adoptive cell transfer therapies (ACTs) have gained significant attention. However, their therapeutic efficacies are limited due to the presence of cold type tumors, immunosuppressive tumor microenvironment, and immune-related side effects. On the other hand, dendritic cell (DC)-based vaccines have been suggested as a new cancer immunotherapy regimen that can address the limitations encountered by ICBs and ACTs. Despite the success of the first generation of DC-based vaccines, represented by the first FDA-approved DC-based therapeutic cancer vaccine Provenge, several challenges remain unsolved. Therefore, new DC vaccine strategies have been actively investigated. This review addresses the limitations of the currently most adopted classical DC vaccine and evaluates new generations of DC vaccines in detail, including biomaterial-based, immunogenic cell death-inducing, mRNA-pulsed, DC small extracellular vesicle (sEV)-based, and tumor sEV-based DC vaccines. These innovative DC vaccines are envisioned to provide a significant breakthrough in cancer immunotherapy landscape and are expected to be supported by further preclinical and clinical studies.

cell biology
Dendritic Cells As Vectors for Immunotherapy of Tumor and Its Application for Gastric Cancer Therapy.

Yugang Wu,Liang Wang,Yanyun Zhang

2004-01-01

Abstract:Dendritic cells (DCs) are recognized as the most potent antigen-presenting cells (APCs) with the ability to stimulate naive resting T cells and initiate primary immune responses. DCs are poised to capture antigen (Ag), migrate to draining lymphoid organs, and, after a process of maturation, select Ag-specific lymphocytes to which they present the processed Ag, thereby inducing immune responses. Numerous studies indicated that immunotherapies utilizing DC-presenting tumor-associated antigens can safely be administered to cancer patients and induce significant immunologic and clinical responses. Moreover, it has been demonstrated that DCs are related to clinical stage, invasion, metastasis and prognosis of gastric cancer. DC-based tumor vaccines become a new effective immunoadjuvant therapy for gastric cancer.
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer

Xin Zhang,Zheng Xu,Xiangpeng Dai,Xiaoling Zhang,Xueju Wang

DOI: https://doi.org/10.3389/fimmu.2023.1104860

IF: 7.3

2023-01-26

Frontiers in Immunology

Abstract:The mutation of the crucial genes such as tumor suppressors or oncogenes plays an important role in the initiation and development of tumors. The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to activate the immune system by activating CD4+ and CD8+ T cells. Neoantigen-based peptide vaccines have exhibited exciting therapeutic effects in treating various cancers alone or in combination with other therapeutic strategies. Furthermore, antigen-loaded DC vaccines are more powerful in inducing stronger immune responses than vaccines generated by antigens and adjuvants. Therefore, neoantigen-based dendritic cell (DC) vaccines could achieve promising effects in combating some malignant tumors. In this review, we summarized and discussed the recent research progresses of the neoantigen, neoantigen-based vaccines, and DC-based vaccine in pancreatic cancers (PCs). The combination of the neoantigen and DC-based vaccine in PC was also highlighted. Therefore, our work will provide more detailed evidence and novel opinions to promote the development of a personalized neoantigen-based DC vaccine for PC.

immunology

Advances in dendritic cells-based for vaccine prostate cancer

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Advances in Research on Dendritic Cell-based Tumor Vaccine

Research of Dendritic Cell Tumor Vaccine

Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

Anti-tumor Immunity with Dendritic Cells ( DC) Vaccine Modified by IL-18

Progress in Biology of Dendritic Cells——Review

Advances in dendritic cells vaccines

The role of dendritic cells in cancer immunity and therapeutic strategies

Advance in the Research of Tumor RNA Transfected Dendritic Cells Vaccine and Its Anti-Neoplastic Application

Dendritic Cells Based Immunotherapy

Advances in Preparation and Clinical Application of Dendritic Cell-Based Tumor Vaccines

Progress of Dendritic Cell in Tumor Immunotherapy

Current state of knowledge and challenges for harnessing the power of dendritic cells in cancer immunotherapy

Dendritic cell biology and its role in tumor immunotherapy

Research progress of dendritic cell and dendritic cell function and vaccine

Development of Dendritic Cell Based for Tumor Gene Immunotherapy

Dendritic cells-based tumor vaccines：advances in research and practice

Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations

Dendritic Cells As Vectors for Immunotherapy of Tumor and Its Application for Gastric Cancer Therapy.

Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer